Opus Genetics, Inc. (IRD)
4.23
+0.03
(+0.71%)
USD |
NASDAQ |
Nov 10, 16:00
4.24
+0.01
(+0.24%)
After-Hours: 20:00
Opus Genetics Enterprise Value : 350.79M for Nov. 10, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 10, 2026 | 350.79M |
| November 09, 2026 | 347.91M |
| November 06, 2026 | 346.00M |
| November 05, 2026 | 329.23M |
| November 04, 2026 | 354.62M |
| November 03, 2026 | 322.05M |
| November 02, 2026 | 300.01M |
| October 30, 2026 | 297.14M |
| October 29, 2026 | 295.22M |
| October 28, 2026 | 298.10M |
| October 27, 2026 | 277.02M |
| October 26, 2026 | 263.61M |
| October 23, 2026 | 277.98M |
| October 22, 2026 | 311.51M |
| October 21, 2026 | 339.77M |
| October 20, 2026 | 329.71M |
| October 19, 2026 | 311.51M |
| October 16, 2026 | 313.43M |
| October 15, 2026 | 333.54M |
| October 14, 2026 | 338.33M |
| October 13, 2026 | 351.75M |
| October 12, 2026 | 390.07M |
| October 09, 2026 | 391.02M |
| October 08, 2026 | 372.82M |
| October 07, 2026 | 368.03M |
| Date | Value |
|---|---|
| October 06, 2026 | 365.16M |
| October 05, 2026 | 365.16M |
| October 02, 2026 | 384.32M |
| October 01, 2026 | 377.61M |
| September 30, 2026 | 409.23M |
| September 29, 2026 | 356.91M |
| September 28, 2026 | 364.76M |
| September 25, 2026 | 340.80M |
| September 24, 2026 | 349.89M |
| September 23, 2026 | 346.58M |
| September 22, 2026 | 373.86M |
| September 21, 2026 | 378.81M |
| September 18, 2026 | 375.51M |
| September 17, 2026 | 383.77M |
| September 16, 2026 | 394.52M |
| September 15, 2026 | 428.40M |
| September 14, 2026 | 440.80M |
| September 11, 2026 | 446.59M |
| September 10, 2026 | 449.06M |
| September 09, 2026 | 420.96M |
| September 08, 2026 | 306.08M |
| September 04, 2026 | 333.36M |
| September 03, 2026 | 327.57M |
| September 02, 2026 | 315.18M |
| September 01, 2026 | 263.93M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Rezolute, Inc. | 299.58M |
| Faeth Therapeutics, Inc. | 166.00M |
| Nuvectis Pharma, Inc. | 400.56M |
| ACADIA Pharmaceuticals, Inc. | 2.254B |
| Alnylam Pharmaceuticals, Inc. | 19.71B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -46.50M |
| Revenue (Quarterly) | 1.137M |
| Total Expenses (Quarterly) | 47.63M |
| EPS Diluted (Quarterly) | -0.4565 |
| Profit Margin (Quarterly) | -4.09K% |
| Earnings Yield | -37.50% |
| Normalized Earnings Yield | -22.78 |